ClinicalTrials.gg
Active, not recruitingNCT06961786TUNINTIL-2Updated Mar 5, 2026

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

A Phase 1 interventional study of TILT-123 and TIL in Metastatic Melanoma, sponsored by TILT Biotherapeutics Ltd.. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by TILT Biotherapeutics Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Melanoma with a site in Denmark — 16 open to participants now, 28 under way, 7 of them phase 3. Melanoma · Denmark.

Planned enrollment
69th of 73
9 · median 134
Started
2025
with 3 others
Phase 1
14 of 86
4 open now
Primary completion
2026-11
later than 16 of 27 live
Registered
82nd of 86
by date

Among the 86 studies in Melanoma with a site in Denmark, this one is the 69th largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 in phase 1, reaches primary completion later than 16 of the 27 other live ones, and was the 82nd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

16 of the 86 studies in Melanoma with a site in Denmark are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Melanoma with a site in Denmark, or all of them as a file.
02

Study summary

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

Read the detailed description

TILT-123 is a tumor-selective replicating oncolytic adenovirus expressing TNFa and IL-2 that is being investigated in several Phase 1 clinical studies in patients with various types of cancer. This is the second study of TILT-123 in patients with metastatic melanoma. Building upon the previous study, TILT-T215, which evaluated the safety and preliminary efficacy of TILT-123 in combination with TILs, Study TILT-T216 will investigate the addition of lymphocyte-depleting chemotherapy to the combination of TILT-123 and TILs. The purpose of lymphodepleting chemotherapy, cyclophosphamide and fludarabine phosphate is to reduce irrelevant T cells and eliminate the regulatory T cells, which are known to be able to inhibit T-cell mediated tumor cell killing.

03

Conditions studied

  • Metastatic Melanoma

Browse trials for

Keywords

  • oncolytic virus
  • TILT
  • immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be 18 to 75 years of age inclusive, at the time of signing the .
  2. Patients with confirmed previously treated or recurrent stage 3-4 melanoma, which cannot be treated with curative intent with available therapies.
  3. Patients who have had at least 1 prior line of medical treatment (eg, , kinase inhibitors, IL-2). Multiple prior therapies (eg, surgery, checkpoint inhibitors, kinase inhibitors, IL-2, interferon, chemotherapy, radiation) are allowed.
  4. Patients must have a demonstrated performance score of 0-1 at screening.
  5. A tumor of >9 mm in diameter (typically a minimum of 1 cm3 in volume), without signs of necrosis, must be available for /operation to enable growing of TILs.
  6. At least 1 additional tumor (>14 mm in diameter) must be available for injections and biopsies for correlative analyses. The disease burden must be evaluable according to 1.1.
  7. Patients must have adequate hepatic, cardiac, and renal function as follows:

    1. ≥ 100,000/µl and \< 700,000/µl
    2. ≥100 g/L
    3. and ALT ≤2.5×
    4. >60 mL/min (CKD-EPI)
    5. Leukocytes (WBC) >3.0G/L
    6. greater than 1500/mm3 without the support of filgrastim
    7. \<1.5×ULN
    8. Patients of 60 years or older, or have a history of ischemic heart disease, chest pain, or atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, heart block, will undergo cardiac evaluation: assessment with documented LVEF ≥ 50% by either TTE (trans thoracal echocardiography) or MUGA (multigated acquisition scan). Further cardiac evaluations in patients with cardiac risk factors (e.g. diabetes, hypertension, obesity) will be evaluated by the investigator as deemed necessary.
  8. Must be willing to use adequate forms of from screening, during the study, and for a minimum of 90 days after the end of treatment, in accordance with the following:

    1. Woman of : Barrier contraceptive method (ie, condom) must be used in addition to 1 of the following methods: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections).
    2. Women not of childbearing potential: Barrier contraceptive method (ie, condom) must be used.
    3. Men: Barrier contraceptive method (ie, condom) must be used.
  9. Patients must be capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  10. Patients must be capable of understanding and complying with the parameters outlined in the protocol.
  11. Patients must have a longer than 3 months.
  12. Patients must be eligible for adoptive T-cell therapy with Lymphocyte-depleting chemotherapy and TILs.

Exclusion criteria

Exclusion Criteria:

  1. History of another active invasive cancer as judged by the investigator within the past 3 years except basal cell carcinoma.
  2. Uncontrolled cardiac or vascular diseases.
  3. History of heart attack or cerebral stroke within the previous 12 months before screening or is not recovered from a previous heart attack or cerebral stroke.
  4. History of hepatic dysfunction, hepatitis, or .

    1. Patients should be seronegative for HIV antibody.
    2. Patients should be seronegative for antigen, and seronegative for antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
  5. History of coagulation disorder.
  6. Untreated . Treated brain metastases that have not progressed in the 3 months prior to screening are allowed.
  7. Concurrent opportunistic and/or active systemic infections.
  8. Use of medications ( or drugs used in treatment of disease), except for the following, which can be allowed at screening and during the study:

    1. Replacement corticosteroids (eg, if the patient has adrenal insufficiency after prior immunotherapy)
    2. Pulmonary and topical treatments
    3. Prednisone/prednisolone at doses up to 20 mg/day
  9. Treated with any anticancer therapy (eg, immunotherapy, signal-transduction inhibitors [eg. BRAF and MEK inhibitors], cytotoxic chemotherapy, radiotherapy, or agents [ie, any drug or therapy that is currently not approved for use in humans]) within 30 days prior to enrollment.
  10. Previously treated with any oncolytic adenovirus that was administered IT.
  11. Previously treated with adoptive cell therapy.
  12. Administered an IMP or device in another clinical study within 30 days prior to baseline.
  13. Lactate dehydrogenase value >5×.
  14. Allergy to any ingredients present in the IMPs (as listed in the respective IBs).
  15. Women of who are pregnant, breastfeeding, or intending to become pregnant.
  16. Any other medical condition or laboratory abnormality that, in the judgment of the principal investigator, could increase the risk associated with study participation, interfere with interpretation of study results, or otherwise render study participation inappropriate.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    TILT-123, TILs and chemotherapy

    TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs

    Biological: TILT-123 · Biological: TIL · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • BiologicalTILT-123

    TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

    Also known as: Ad5/3-E2F-d24-hTNFa-IRES-hIL2

  • BiologicalTIL

    Adoptive T cell therapy with TILs

    Also known as: Tumor-infiltrating lymphocytes

  • Lymphocyte-depleting chemotherapy

    Also known as: Cytoxan, cyclophosphane

  • Lymphocyte-depleting chemotherapy

    Also known as: Fludara

06

What researchers measure

Primary outcomes

  1. Number of Participants with any (serious and non-serious) Adverse Events

    Adverse events

    Time frame: 78 days

  2. Number of Participants with abnormal laboratory values

    Laboratory values

    Time frame: 78 days

  3. Number of Participants with vital sign abnormalities

    Vital signs

    Time frame: 78 days

  4. Safety assessed by 12- lead electrocardiograms (ECGs) Adverse Events

    Clinically significant abnormalities detected in the evaluation (including for example rate, rhythm, axis calculations and interpretation of P, Q, R, S, T U waves, segments and basic ECG calculations) will be recorded

    Time frame: 78 days

07

Study locations

1 site
  • National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
    Copenhagen, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 17 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 8, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Apr 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961786
Lead sponsor
TILT Biotherapeutics Ltd.
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Jun 25, 2025
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Inge Marie Svane
principal investigator · CCIT, Herlev Hospital, Copenhagen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Igrelimogene litadenorepvec

Start the discussion